皇冠篮球比分网

  Profile Core value Main business Legitimacy Social Responsibility
    Patents Research Direction Technology Strength
  API Intermediates Side chain for Paclitaxel and Docetaxel N-1 stage
  Production management QC Quality System branch factory
 
logn  
  home
 
  Products Center
  API
Paclitaxel (Semi-synthetic)
Paclitaxel (Natural)
Docetaxel Anhydrous
Docetaxel Trihydrate
Cabazitaxel
Irinotecan HCl Trihydrate 99.5%
Etoposide USP31
Palonosetron Hydrochloride
  N-1 stage of Paclitaxel and Docetaxel
7-Troc-Paclitaxel
7,10-di-Troc-Docetaxel
more...
  Main Intermediates
10-Deacetylbaccatin III
Baccatin III
more...
  Side chain for Paclixel semi-Synthetic
(4S,5R)-3-(N-benzoyl)-2,2-dimethyl-4-phenyloxazolidine-5-carboxylic acid
  Side chain of Docetaxel
(4S,5R)-3-(N-tert-butoxycarbony)-2,2-dimethyl-4-phenyloxazolidine-5-carboxylic acid
  Side chain for Paclitaxel and Docetaxel
(3R,4S)-3-hydroxy-4-phenyl-2-azetidinone
Ethyl (2R,3S)-3-Phenylisoserine Ester
more...
Your location >>Home>>About us>>profile
 
 
Shanghai Jinhe Bio-Pharmaceutical Co., Ltd. (Abrr. "Jinhe") , founded in March 2002, is a pharmaceutical enterprise dedicated to R&D, manufacturing and marketing anti-cancer APIs and their intermediates. Based on the R&D achievement of Fudan University, we began to undertake the international business of processing Paclitaxel API. After years of effort, we successfully developed Paclitaxel, Docetaxel, Irinotecan, Etoposide etc, from natural extracting anti-cancer products into material source anti-cancer APIs. In recent years, we developed new APIs, such as Cabazitaxel, Palonosetron hydrochloride etc. In 2012, we cooperated with Shanghai Zhongxi Sunve Pharmaceutical Co.,Ltd, (Abrr. "Sunve") became a member of Shanghai Pharmaceuticals Holding Co.,Ltd. (Abrr. "SPH"). Since then, we targeted ourselves as the production base of SPH on oncology products. In 2015, we and Shanghai Huayu Chinese Herbs Co., Ltd. (Abrr. "Huayu") both subsidiaries of SPH, reorganized Dali Zhonggu Yew Biological Co., Ltd. (Abrr. "Zhonggu Biological") by way of investment in cash. This move indicates that SPH will further integrate its oncology drug industry chain and build its advantage in APIs. In January 2017, we achieved GMP certificate on Bulk Drug (Paclitaxel, Docetaxel). We are always committed to be a competitive and responsible company in global pharmaceutical industry.

   
CopyRight(C)2006, All Rights Reserved. Supported by    Copyright Notice
HOME About us Products R & D Production and QA Contact us CHINESE